75 results
8-K
EX-99.1
PLSE
Pulse Biosciences Inc
20 May 24
Pulse Biosciences Announces Updated Timing of Rights Offering for Up to $60,000,000
4:10pm
over current treatment options, statements concerning the timing and nature of the Company’s pilot program to optimize and introduce the CellFX nsPFA
8-K
EX-10.3
PLSE
Pulse Biosciences Inc
15 May 24
Pulse Biosciences Enhances Executive Leadership Team
9:05am
, WITH OR WITHOUT CAUSE.
9. Nature of Grant. In accepting the Option, Participant acknowledges, understands and agrees that:
(a) the grant of the Option … a description of the Plan. Participant understands that the Plan is discretionary in nature and may be amended, suspended or terminated by the Company at any
8-K
EX-99.1
PLSE
Pulse Biosciences Inc
9 May 24
Pulse Biosciences Announces First U.S. Procedure with the CellFX nsPFA Percutaneous Electrode System
9:09am
, statements concerning the timing and nature of the Company’s pilot program to optimize and introduce the CellFX nsPFA percutaneous procedure
8-K
EX-99.1
bdb1 gnre
2 Jan 24
Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX® nsPFA™ Cardiac Clamp
9:20am
8-K
7h0q4ce 21lco
27 Nov 23
Regulation FD Disclosure
9:08am
8-K
EX-99.1
5s8l9k qb1n2
21 Nov 23
Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX nsPFA Percutaneous Electrode
9:03am
8-K
EX-10.1
0bguou vn8i
1 May 23
Pulse Biosciences Announces $65 Million Private Placement
4:15pm